Excellent Nutraceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 05-01-2025
- Paid Up Capital ₹ 0.10 M
as on 05-01-2025
- Company Age 14 Year, 9 Months
- Last Filing with ROC 31 Mar 2019
- Revenue 109.07%
(FY 2019)
- Profit 46.85%
(FY 2019)
- Ebitda 241.80%
(FY 2019)
- Net Worth 41.61%
(FY 2019)
- Total Assets 0.76%
(FY 2019)
About Excellent Nutraceuticals
The Corporate was formerly known as Excell Nutraceuticals Private Limited. The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Anandam Sinha, Rajeev Kumar, Rakesh Sinha, and Three other members serve as directors at the Company.
- CIN/LLPIN
U24100DL2010PTC199995
- Company No.
199995
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Mar 2010
- Date of AGM
30 Sep 2019
- Date of Balance Sheet
31 Mar 2019
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Excellent Nutraceuticals?
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anandam Sinha  | Director | 12-Mar-2010 | Current |
| Rajeev Kumar | Director | 12-Mar-2010 | Current |
| Rakesh Sinha | Director | 12-Mar-2010 | Current |
| Meeta Sinha | Director | 12-Mar-2010 | Current |
| Binay Kumar | Director | 12-Mar-2010 | Current |
| Rajiv Kumar | Director | 12-Mar-2010 | Current |
Financial Performance of Excellent Nutraceuticals.
Excellent Nutraceuticals Private Limited, for the financial year ended 2019, experienced significant growth in revenue, with a 109.07% increase. The company also saw a substantial improvement in profitability, with a 46.85% increase in profit. The company's net worth Soared by an impressive increase of 41.61%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Excellent Nutraceuticals?
In 2017, Excellent Nutraceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Exhar Formulations Private LimitedActive 17 years 8 monthsAnandam Sinha, Rajeev Kumar and 4 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Excellent Nutraceuticals?
Unlock and access historical data on people associated with Excellent Nutraceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Excellent Nutraceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Excellent Nutraceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
